Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Limited announced positive results from its EFTISARC-NEO Phase II trial, which evaluated the novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® in treating resectable soft tissue sarcoma (STS). The trial met its primary endpoint, achieving a 51.5% tumor hyalinization/fibrosis rate, significantly surpassing the historical 15% rate from standard radiotherapy alone. This outcome suggests potential improvements in overall and recurrence-free survival for STS patients, addressing a critical unmet medical need. The findings, presented at the ESMO Congress 2025, highlight the promising efficacy and safety profile of efti, potentially paving the way for new therapeutic options in STS treatment.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to harness its potential to stimulate or suppress immune responses. Immutep’s diversified product portfolio includes treatments for various cancers, such as non-small cell lung cancer, head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer.
YTD Price Performance: -16.44%
Average Trading Volume: 2,551,043
Technical Sentiment Signal: Buy
Current Market Cap: A$448.9M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.